Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Curr Opin Virol. 2017 May 10;24:70–78. doi: 10.1016/j.coviro.2017.03.015

Table 1.

Advantages and disadvantages of the main strategy categories for RSV vaccine development.

Live-attenuated
(For young infants and children <24 months of age)		 Advantages Disadvantages

  • Induces immunity

  • Does not exacerbate future RSV exposure

  • Administered intranasally

  • Need to obtain delicate balance between immunogenicity and adequate attenuation
Vector delivery system
(For young infants and children <24 months of age)

  • Induced potent cellular and humoral responses in a primate model and preclinical studies

  • Safer option than live attenuated vaccines in children with no risk of insufficient attenuation

  • Prior exposure to the vector and immunological memory against common serotypes may reduce the immune response and limit their use

  • The potential oncogenicity and pathogenicity of some Adenovirus serotypes
Protein-based
(For pregnant women and elderly)

  • Maternal immunization could increase transplacental antibody transfer and provide immunity for infants

  • High risk of exacerbation for RSV-naïve infants